CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Thursday, Vertex Pharmaceuticals Inc.
(VRTX) announced that the FDA has cleared the Investigational New Drug
Application or IND for VX-407 for the treatment of autosomal dominant polycystic
kidney disease or ADPKD.

VX-407 is a small molecule corrector that targets the root cause of ADPKD, a
genetic kidney disease that shortens life expectancy.

ADPKD affects patients with specific PKD1 genetic variations and is
characterized by the development of multiple kidney-enlarging cysts. These cysts
impair kidney function and can eventually result in kidney failure,
necessitating dialysis or a kidney transplant, and causing premature death.

The company is also planning to initiate a Phase 1 clinical trial in healthy
volunteers this month.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX